Medicare Part D coverage · 12 · RxCUI 902648
12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace]
Per the CMS 2026 Part D formulary file, 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] is covered by 788 Medicare Part D plans (15.6% of enrollable products), averaging Tier 3.6, with prior authorization required on 8% of covering formularies.
- 15.6%
- Plan coverage
- 788
- Plans covering
- T3.6
- Avg tier
- 8%
- Prior auth required
What the CMS Formulary Data Shows for 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace]
Per the CMS 2026 Part D formulary file, 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] (RxNorm concept RXCUI 902648, generic name 12) appears on 25 distinct formulary files spanning 788 Medicare Part D plan offerings - 15.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.6.
Real-world access to 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] depends on utilization management as much as tier placement: 8% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 11 Part D beneficiaries filled 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] in 2023, with total plan-and-beneficiary spending of $32,331 and an average per-beneficiary annual cost of $2,939.14. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] today.
Coverage Details
- Formularies covering
- 25
- Plans covering
- 788
- Coverage rate
- 15.6%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 8% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 11
- Total spending
- $32,331
- Avg per beneficiary
- $2,939.14
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] covered by Medicare Part D?
Yes, 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] is covered by 788 Medicare Part D plans (15.6% of all Part D formularies).
What tier is 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] on Medicare Part D plans?
12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] averages Tier 3.6 across Part D plans, ranging from Tier 1 to Tier 4.
Does 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] require prior authorization?
8% of Part D formularies require prior authorization for 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace]?
In 2023, total Medicare Part D spending on 12 HR disopyramide 100 MG Extended Release Oral Capsule [Norpace] was $32,331, covering 11 beneficiaries. The average spend per beneficiary was $2,939.14.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- ciprofloxacin 2 MG/ML / hydrocortisone 10 MG/ML Otic Suspension [Cipro HC] T3.6
- alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/10] T3.6
- theophylline 200 MG Extended Release Oral Capsule [Theo-24] T3.6
- azelaic acid 150 MG/ML Topical Foam [Finacea] T3.6
- clindamycin 100 MG Vaginal Insert [Cleocin] T3.6
- eslicarbazepine acetate 200 MG Oral Tablet T3.6